Medical Dizziness Animations

Phase IIa Clinical Trial Results Relating To CK-1827452 In Patients With Ischemic Cardiomyopathy And Angina
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today top-line results from a Phase IIa clinical trial evaluating the safety of CK-1827452 in patients with ischemic cardiomyopathy and angina.  The primary safety endpoint was defined as stopping an exercise test during treatment with CK-1827452 (versus placebo) due to unacceptable angina at an earlier exercise stage than at baseline.

Hormones Increase Frequency Of Inherited Form Of Migraine In Women
Familial hemiplegic migraine (FHM) is an inherited form of severe migraine that is accompanied by visual disturbances known as aura. As with other types of migraine, it affects women more frequently than men. Most cases of FHM are caused by mutations in the CACNA1A gene, but whether these lead to spreading depression, the event in the brain that suppresses nerve cell activity and that has been linked to nongenetic forms of migraine with aura, has not been determined.

Addex Starts A Phase IIb Trial Of ADX10059 For Migraine Prevention
Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 as a migraine prevention therapy in people who suffer from 3 or more migraine attacks per month. ADX10059 is a first-in-class migraine prophylactic which works by inhibiting the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM). Addex believes mGluR5 may be a key player in a neural process that initiates migraine headaches.

Help For Children And Teenagers Who Suffer From Migraines
Chocolate, excitement and the stress of Christmas: these are not just a headache for parents. They are also responsible for triggering migraines in many young people. Learning how to manage stress and avoid triggers are just as important as getting the right medication.

Telcagepant Proven As A Safe And Effective Migraine Treatment In Phase III Trial
Telcagepant 300 mg is effective as an acute treatment for migraine with efficacy comparable to that of zolmitriptan 5 mg, a widely-used migraine treatment, but with fewer associated adverse effects. These are the conclusions of an Article published Online first and in and upcoming edition of The Lancet, written by Dr Tony Ho, Merck Research Laboratories, North Wales, Philadelphia, USA, and colleagues.

Patent Foramen Ovale Closure Extremely Promising For Stroke Prevention And Treatment Of Migraine
There continues to be a disagreement between the neurological and vascular communities as to when to close the PFO (Patent Foramen Ovale) - the hole in the heart between the right and left atria): the former state that it should be done only after the occurrence of the second stroke, with anticoagulation medicines administered after the first stroke, and this is currently the prevailing practice.

Overuse Of Narcotics And Barbiturates May Make Migraine Worse
A team of researchers led by investigators at the Albert Einstein College of Medicine of Yeshiva University has determined that certain commonly-prescribed medications may have the unintended consequence of increasing the frequency of migraine attacks. This important finding could alter the way doctors prescribe migraine medicines.

1 In 4 Gulf War Veterans Suffer From Illness Caused By Toxic Exposure
At least one in four of the 697,000 U.S. veterans of the 1991 Gulf War suffer from Gulf War illness, a condition caused by exposure to toxic chemicals, including pesticides and a drug administered to protect troops against nerve gas, and no effective treatments have yet been found, a federal panel of scientific experts and veterans concludes in a landmark report released Monday.

500-Patient Study Measuring Cognitive Processing Efficiency During Migraine Attacks
PHT Corporation, the market-leading provider of electronic patient reported outcome (ePRO) solutions used in more than 360 clinical trials worldwide, is providing its innovative LogPad(R) System to help headache experts at Clinvest Clinical Research measure cognitive deficits during migraine attacks in a sponsored clinical trial. This is the first time cognitive processing time has been tested in a major migraine research study.

Breakthrough's Comment On Research Suggesting Women Who Have Migraines Have A Reduced Risk Of Breast Cancer
Research to be published in Cancer Epidemiology, Biomarkers and Prevention suggests that women who suffer from migraines may have a reduced risk of developing certain types of breast cancer. Dr Sarah Cant, Policy Manager at Breakthrough Breast Cancer, says: "This small study is the first to suggest that women who suffer migraines may have a reduced risk of developing certain types of breast cancer, so needs to be backed up by further research.

Pycnogenol Cut Jetlag Symptoms In Half For Passengers Taking 7- To 9-hour Flights
A new study published in the journal of Minerva Cardioangiologica reveals Pycnogenol, pine bark extract from the French maritime pine tree, reduces jetlag in passengers by nearly 50 percent. The two-part study, consisting of a brain CT scan and a scoring system, showed Pycnogenol lowered symptoms of jetlag such as fatigue, headaches, insomnia and brain edema (swelling) in both healthy individuals and hypertensive patients.

Women Who Have Migraines Have Lower Breast Cancer Risk
Women who suffer from migraines may take at least some comfort in a recent, first-of-its-kind study that suggests a history of such headaches is associated with a significantly lower risk of breast cancer. Christopher I. Li, M.D., Ph.D., and colleagues at Fred Hutchinson Cancer Research Center report these findings in the November issue of Cancer Epidemiology, Biomarkers and Prevention.

Doctors Stress Pressing Need For Research Into The Best Treatment For Medication Overuse Headaches
There is a critical need to review current treatment strategies for the increasingly common problem of medication overuse headaches (MOH), according to a series of international papers in the November issue of Cephalalgia. "MOH is associated with severe disability, unmet treatment need and little clinical data to support current management strategies" says neurology expert Professor David W Dodick from the Mayo Clinic College of Medicine, Arizona, USA.

Minster Pharmaceuticals Plc Announces Positive Results From Phase II Trial Of Migraine With Aura
Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of migraine with aura. The median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo.

Targeting Neuropeptides Could Be Future For Migraine Treatment
Targeting a system which utilises peptides in the brain during a migraine could be the future of treatment for this debilitating condition. The future and recent developments in the field of migraine are discussed in a Comment in this week's edition of The Lancet, written by Dr Stephen D Silberstein, Thomas Jefferson University, Philadelphia, PA, USA.